ArticleScientific reports2016
Interleukin-31 expression and relation to disease severity in human asthma.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Thymic stromal lymphopoietin expression in different biological specimens in asthma: a systematic review and meta-analysis.Frontiers in allergy · 2025Pooled it
- IL-31: State of the Art for an Inflammation-Oriented Interleukin.International journal of molecular sciences · 2022Pooled it
- IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases.International journal of molecular sciences · 2019Pooled it
- Roles of Interleukin-31 in Allergen-Driven Cough: Linking Protease-Activated Receptor-2 Activation and Vagal Ganglion Sensitization in a Dermatophagoides farinae-Induced Asthma Model.Brain and behavior · 2026Article
- Oncostatin M receptor deficiency as a novel candidate genetic cause of autosomal recessive hyper-IgE syndrome.Journal of human immunity · 2026Article
- Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX-622.Allergy · 2025Article
- A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis.JAAD case reports · 2025Article
- Emerging Concepts in Cytokine Regulation of Airway Remodeling in Asthma.Immunological reviews · 2025Review
- Interleukin-31 in Respiratory Type 2 Inflammatory Diseases: Mechanistic Insights and Therapeutic Potential.Journal of inflammation research · 2025Review
- Article
- Biomarkers of type 2 and non-type 2 inflammation in asthma exacerbations.Central-European journal of immunology · 2024Article
- Interleukin 31 receptor α promotes smooth muscle cell contraction and airway hyperresponsiveness in asthma.Nature communications · 2023Article
- IL-31-Pruritus Interleukin: Serum Values and Clinical Impact in Chronic Spontaneous Urticaria-A Romanian Retrospective Study.Journal of clinical medicine · 2023Article
- The IL-33/IL-31 Axis in Allergic and Immune-Mediated Diseases.International journal of molecular sciences · 2023Article
- Transcriptomics reveals a distinct metabolic profile in T cells from severe allergic asthmatic patients.Frontiers in allergy · 2023Article
- Increased IL-31 expression in serum and tissue protein in prurigo nodularis.Therapeutic advances in chronic disease · 2022Article
- Difference of Serum Cytokine Profile in Allergic Asthma Patients According to Disease Severity.Journal of asthma and allergy · 2022Article
- Mesenchymal stromal cell apoptosis is required for their therapeutic function.Nature communications · 2021Article
- Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis.Nature communications · 2021Article
- IL-31 transgenic mice show reduced allergen-induced lung inflammation.European journal of immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin 31 (IL-31) is a novel T helper type 2 effector cytokine that plays an important role in the pathogenesis of allergic diseases. However, its role in human asthma remains unclear. The aim of this study was to measure IL-31 levels in the serum, bronchoalveolar lavage fluid (BALF) and bronchial tissue of asthmatics and healthy subjects, and identify its possible correlation to disease severity. We quantified IL-31 levels in the serum of patients with asthma (n = 44), as well as in controls (n = 22). Of these subjects, 9 asthmatics and five controls underwent bronchoscopy with endobronchial biopsy and BALF collection. Our data showed that serum and BALF IL-31 levels were significantly elevated in patients with asthma compared with controls. Expressions of IL-31 and IL-31 receptor (IL-31RA and OSMR) were more prominent in the bronchial tissue in severe compared to mild asthma and controls. Serum IL-31 levels correlated positively with Th2 related cytokines (IL-5, IL-13, and TSLP), asthma severity or total serum immunoglobulin E (IgE), and inversely with asthma control and the forced expiratory volume in 1 second (FEV1). The current data may provide insight into the underlying pathogenesis of asthma, in which IL-31 has an important pathogenic role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.